• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Research Fellows
    • Our History
    • Corporate Social Responsibility
    • Environmental Sustainability
  • R&D
    • Clinical Pipeline
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / 2014 EHA: Results of a Randomized Multicenter Phase 2 Study of a 5-day...

2014 EHA: Results of a Randomized Multicenter Phase 2 Study of a 5-day Regimen of SGI-110

25 June 2014/in Uncategorised

2014 EHA: Results of a Randomized Multicenter Phase 2 Study of a 5-day Regimen of SGI-110

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2014-06-25 15:47:572016-12-01 12:49:212014 EHA: Results of a Randomized Multicenter Phase 2 Study of a 5-day Regimen of SGI-110

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: 2014 BACR: Characterisation of the Activity of Potent XIAP/cIAP1 Dual Antagonists in Melanoma Models Link to: 2014 BACR: Characterisation of the Activity of Potent XIAP/cIAP1 Dual Antagonists in Melanoma Models 2014 BACR: Characterisation of the Activity of Potent XIAP/cIAP1 Dual Antagonists... Link to: 2014 AACR: AT13387 combined with erlotinib improves response in EGFR-driven xenograft models of NSCL Link to: 2014 AACR: AT13387 combined with erlotinib improves response in EGFR-driven xenograft models of NSCL 2014 AACR: AT13387 combined with erlotinib improves response in EGFR-driven...
Scroll to top Scroll to top Scroll to top